trial

A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults

NCTId NCT07455084
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Not Yet Recruiting
Enrollment 8 (estimated)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2026-04-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Not Yet Recruiting
Enrollment
8 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2026-03-20
Primary completion
2026-04-10
Eligibility
MALE · 18 Years · 55 Years

Interventions & indications

Drugs
14C-SEP-380135

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

1 total
Lincoln, United States

Facts & assertions

4 sourced
Enrollment
8
Phase
PHASE1
Primary Completion Date
2026-04-10
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
14C-SEP-380135
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication